Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

Abstract Background The use of checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) has revolutionised the treatment of metastatic melanoma. However still more than the half the patients do not respond to single-agent immunotherapy. This has led to the development of combining these agents i...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Journal of Translational Medicine
المؤلفون الرئيسيون: Angus G. Dalgleish, Satvinder Mudan, Alberto Fusi
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2018-08-01
الموضوعات:
Checkpoint blockade
Melanoma
IMM-101
Immunotherapy
Mycobacteria
الوصول للمادة أونلاين:http://link.springer.com/article/10.1186/s12967-018-1602-8

الانترنت

http://link.springer.com/article/10.1186/s12967-018-1602-8

مواد مشابهة